Cargando…

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A

OBJECTIVES: Inhibition of pregnancy-associated plasma protein-A (PAPP-A), an upstream activator of the insulin-like growth factor (IGF) pathway, is known to augment sensitivity to platinum-based chemotherapy. This study further tests the efficacy of PAPP-A inhibition with a monoclonal antibody inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, Diogo, Hou, Xiaonan, Bale, Laurie, Heinzen, Ethan P., Maurer, Matthew J., Zanfagnin, Valentina, Oberg, Ann L., Conover, Cheryl, Weroha, S. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872139/ https://www.ncbi.nlm.nih.gov/pubmed/31751381 http://dx.doi.org/10.1371/journal.pone.0224564

Ejemplares similares

ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer
por: Kanakkanthara, Arun, et al.
Publicado: (2019)

Inducible knockdown of pregnancy‐associated plasma protein‐A gene expression in adult female mice extends life span
por: Bale, Laurie K., et al.
Publicado: (2017)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts()()
por: Butler, Kristina A., et al.
Publicado: (2017)

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting
por: Oberg, Ann L., et al.
Publicado: (2021)

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts
por: Liu, Yuanhang, et al.
Publicado: (2019)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
por: Kladnik, Jerneja, et al.
Publicado: (2021)

Cellular characterization of human epicardial adipose tissue: highly expressed PAPP‐A regulates insulin‐like growth factor I signaling in human cardiomyocytes
por: Conover, Cheryl A., et al.
Publicado: (2019)

Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
por: Cotler, Max J., et al.
Publicado: (2022)

An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2015)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study
por: Michalak, Marcin, et al.
Publicado: (2020)

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
por: Huang, Dongqing, et al.
Publicado: (2021)

Platinum nanoparticles: an exquisite tool to overcome radioresistance
por: Li, Sha, et al.
Publicado: (2017)

Corrigendum: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2016)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)

ADAM17 inhibition enhances platinum efficiency in ovarian cancer
por: Hedemann, Nina, et al.
Publicado: (2018)

Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft
por: Glaser, Gretchen, et al.
Publicado: (2015)

Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2020)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
por: Jeon, Jaewan, et al.
Publicado: (2021)

A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies
por: Dadgar, Neda, et al.
Publicado: (2020)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
por: Harris, Faye R., et al.
Publicado: (2018)

2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion
por: Khamaisi, Hazem, et al.
Publicado: (2022)

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2022)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
por: Shuford, Stephen, et al.
Publicado: (2019)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells
por: Granados, Michaela L., et al.
Publicado: (2015)

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial–Mesenchymal transition
por: Duan, Xirui, et al.
Publicado: (2022)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_dfo7quoh0ohllhq1a6i8er3gcg